Stockscreener 앱 받기
10.35
1.90%
-0.20
시장 영업 전:
10.84
0.49
+4.73%
전일 마감가:
$10.55
열려 있는:
$10.42
하루 거래량:
921.57K
Relative Volume:
0.52
시가총액:
$1.18B
수익:
$655.35M
순이익/손실:
$-136.23M
주가수익비율:
-8.4676
EPS:
-1.2223
순현금흐름:
$-75.68M
1주 성능:
-5.05%
1개월 성능:
-20.63%
6개월 성능:
-26.91%
1년 성능:
-37.69%
1일 변동 폭
$10.13
$10.48
1주일 범위
$10.13
$11.30
52주 변동 폭
$9.82
$20.06
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
10.35 | 1.18B | 655.35M | -136.23M | -75.68M | -1.2223 |
ABT
Abbott Laboratories
|
101.83 | 176.95B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.07 | 127.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.42 | 110.95B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
61.86 | 91.93B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.84 | 46.61B | 6.07B | 1.06B | 1.34B | 1.8063 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-12-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-10-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
Aug Sectors: Can NovoCure Limited stock double in the next yearEarnings Performance Report & AI Forecasted Stock Moves - baoquankhu1.vn
Evercore Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $16 - Moomoo
NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer - Sahm
JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (038.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
NovoCure Limited (NVCR) stock price, news, quote and history - Yahoo Finance UK
SG Americas Securities LLC Boosts Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer - MSN
NovoCure (NVCR) Is Down 6.6% After Strong PANOVA-4 Phase 2 Data In Metastatic Pancreatic Cancer – Has The Bull Case Changed? - Yahoo Finance
NovoCure Ltd to release first quarter 2026 financial results on April 30 - Traders Union
Novocure will post Q1 results before market open on April 30 - stocktitan.net
NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
NovoCure’s EF-32 Optune® Trial Reaches Completion, Setting Up a Key Catalyst for NVCR Investors - TipRanks
A Look At NovoCure (NVCR) Valuation After Extended Share Price Weakness - simplywall.st
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $49 - Moomoo
NovoCure Limited Files 8-K Report Detailing Tumor Treating Fields Therapy and Corporate Information March 2026 - Minichart
NovoCure Ltd (NVCR) Stock Price, Quote, News & History - Benzinga
Vanguard disaggregates ownership reporting for Novocure (NVCR) after realignment - stocktitan.net
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Does Positive PANOVA-4 Data Alter the Bull Case For NovoCure’s TTFields Platform (NVCR)? - simplywall.st
Brain Cancer Market Growth in Future Scope 2026-2033 | Novocure, - openpr.com
Novocure (NVCR) Reports Positive Phase 2 Results for TTFields Th - GuruFocus
Novocure (NVCR) Achieves Key Milestone in Pancreatic Cancer Tria - GuruFocus
Novocure reports positive Phase 2 trial results for pancreatic cancer By Investing.com - Investing.com India
Novocure stock rises on positive pancreatic cancer trial data By Investing.com - Investing.com Australia
PANOVA-4 Phase 2 trial shows promising TTFields therapy results, NovoCure Ltd reveals - Traders Union
Novocure (NASDAQ: NVCR) reports positive PANOVA-4 pancreatic cancer data - Stock Titan
Pancreatic cancer trial posts 74.4% disease control with Novocure - Stock Titan
Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump - Yahoo Finance
Tudor Investment Corp ET AL Purchases 354,216 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Position Lifted by Algert Global LLC - MarketBeat
Capital World Investors Lowers Holdings in NovoCure Limited $NVCR - MarketBeat
FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer - Digital Health News
NovoCure Limited $NVCR Shares Acquired by American Century Companies Inc. - MarketBeat
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment By Investing.com - Investing.com South Africa
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment - Investing.com Australia
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story? - Sahm
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment - Yahoo Finance
Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua - Sahm
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Insider Selling: NovoCure (NASDAQ:NVCR) Insider Sells 1,100 Shares of Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CFO Sells $85,343.72 in Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CEO Sells $74,629.17 in Stock - MarketBeat
Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock - MarketBeat
NovoCure (NASDAQ:NVCR) COO Mukund Paravasthu Sells 43,246 Shares - MarketBeat
NVCR Crosses Above Key Moving Average Level - Nasdaq
Tax-driven sale: NovoCure (NVCR) ex-CMO offloads 1,100 shares to cover RSU taxes - Stock Titan
NovoCure (NVCR) General Counsel receives new stock options and RSU grants - Stock Titan
NovoCure (NASDAQ: NVCR) CMO reports tax sale and new stock awards - Stock Titan
Mukund Paravasthu sells Common shares via Morgan Stanley (NVCR) - stocktitan.net
[144] NovoCure Ltd SEC Filing - Stock Titan
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Novocure Ltd 주식 (NVCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Weinberg Uri | Chf Medical and Innovation Ofr |
Mar 04 '26 |
Sale |
13.31 |
6,412 |
85,314 |
267,190 |
| Brackmann Christoph | Chief Financial Officer |
Mar 04 '26 |
Sale |
13.31 |
6,412 |
85,314 |
182,842 |
| Leonard Frank X | Chief Executive Officer |
Mar 04 '26 |
Sale |
13.31 |
5,607 |
74,603 |
493,793 |
| Paravasthu Mukund | Chief Operating Officer |
Mar 05 '26 |
Sale |
13.77 |
43,246 |
595,670 |
72,832 |
| Paravasthu Mukund | Chief Operating Officer |
Mar 04 '26 |
Sale |
13.31 |
5,377 |
71,543 |
116,078 |
| Puri Michal Nath | Chief Human Resources Officer |
Mar 04 '26 |
Sale |
13.31 |
1,100 |
14,636 |
201,322 |
| DOYLE WILLIAM F | Executive Chairman |
Mar 03 '26 |
Sale |
12.98 |
71,887 |
932,883 |
328,397 |
0.44%
0.34%
자본화:
|
볼륨(24시간):